Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2017

View Archived Issues

Momenta Pharmaceuticals and CSL to develop Fc multimer proteins

Oncoprex shows positive interim results in phase II NSCLC study

Viamet Pharmaceuticals reports results from phase II studies of VT-1161

Ocera Therapeutics' oral OCR-002 shows favorable absorption and pharmacokinetics in phase I study

Minomic gives update on first-in-human study of MILGa

Novartis enters collaboration and option agreement with Ionis and Akcea

ProMIS Neurosciences names first lead product for Alzheimer's disease

FDA clears Sangamo's IND for hemophilia A gene therapy

Okogen enters agreement with Ora for development of OKG-0301

Afstyla approved in E.U. for hemophilia A

ARIAD enters into definitive agreement to be acquired by Takeda

Kite Pharma partners with Daiichi Sankyo for KTE-C19 in Japan

University College Dublin patents prostanoid TP antagonists

Pfizer describes BET protein inhibitors for cancer

KRICT reports PI3Kdelta inhibitors

Biorestorative Therapies submits IND for lead cell therapy candidate

Enzyvant Sciences enters agreement with Duke University for RVT-802

Phase II results for crizanlizumab as prevention of pain crises in patients with sickle cell disease

ThromboGenics initiates phase II trial of THR-317 for diabetic macular edema

Novel immune cell-mediated nanoparticle targeting strategy for the delivery of melanoma drug

Topline results from phase III study of glecaprevir/pibrentasvir for HCV in Japanese patients

Alexion Pharmaceuticals applies to expand indications of Soliris in E.U. and U.S.

FDA grants orphan drug designation to combination of TG-1101 and TGR-1202

Aralez Pharmaceuticals submits MAA for PA-10040 in E.U.

MabVax files IND in U.S. for MVT-1075

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...